Two-dimensional (2D) perovskites are increasingly recognized as promising candidate materials for the next generation of ...

CHUNGCHEONG PROVINCE, South Korea, July 2, 2026 /PRNewswire/ -- Two-dimensional (2D) perovskites have emerged as promising optoelectronic materials. However, their practical and rational design is ...

Implementation sits outside Part D, with Humana handling PA, adjudication, and reimbursement; manufacturers provide a $245 net price for Wegovy, Zepbound, and orforglipron. Eligibility requires PA and ...

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

The construction of the Gordie Howe International Bridge and its customs plazas in Detroit and Windsor is nearing completion, setting the stage for a potential standoff with President Donald Trump ...

The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from insurers. The Centers for Medicare & Medicaid Services first announced the ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Diffusing oxygen into 2D materials can improve adhesion properties. Channel-last processes can preserve most of the traditional gate-all-around process flow. Dual-gate MoS 2 FETs with graphene ...

PARIS — RAS Luxury Skincare, the Indian farm-to-face brand, closed a 65 Crores, or $7.5 million, Series B funding round led by Dabur Ventures. Dabur Ventures is the venture arm of the largest ...

The era of size inclusivity is seemingly over. Our critic traces the shift and hopes designers might learn from it. By Vanessa Friedman I know models have always been skinny, but it seems to me they ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people. These ...